| Entry |
|
|---|
| Name |
Entecavir (USP);
Entecavir hydrate (JAN);
Baraclude (TN) |
|---|
| Product |
|
|---|
| Generic |
ENTECAVIR (Accord Healthcare), ENTECAVIR (American Health Packaging), ENTECAVIR (Amneal Pharmaceuticals LLC), ENTECAVIR (Aurobindo Pharma Limited), ENTECAVIR (AvKARE), ENTECAVIR (AvPAK), ENTECAVIR (Breckenridge Pharmaceutical), ENTECAVIR (BrightGene Bio-Medical Technology), ENTECAVIR (Cadila Healthcare Limited), ENTECAVIR (Camber Pharmaceuticals), ENTECAVIR (Cipla USA), ENTECAVIR (EPIC PHARMA), ENTECAVIR (Golden State Medical Supply), ENTECAVIR (NorthStar RxLLC), ENTECAVIR (Pharmadax), ENTECAVIR (Solco Healthcare LLC), ENTECAVIR (Sunshine Lake Pharma), ENTECAVIR (Teva Pharmaceuticals USA), ENTECAVIR (Yaopharma), ENTECAVIR (Zydus Pharmaceuticals (USA)) |
|---|
| Formula |
C12H15N5O3. H2O
|
|---|
| Exact mass |
295.1281
|
|---|
| Mol weight |
295.2945
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antiviral
DG01890 Nucleoside reverse transcriptase inhibitor (NRTI)
|
|---|
| Remark |
| Therapeutic category: | 6250 |
| Product (DG00661): | D04008<JP/US> |
|
|---|
| Efficacy |
Antiviral, Reverse transcriptase inhibitor |
|---|
| Disease |
|
|---|
| Target |
RNA-directed DNA polymerase |
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AF Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF10 Entecavir
D04008 Entecavir (USP) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-hepatitis B (HBV) Agents
Entecavir
D04008 Entecavir (USP)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D04008 Entecavir (USP); Entecavir hydrate (JAN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04008
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04008
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04008
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04008
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 21
1 O0 O 30.7234 -17.2838
2 C8y C 23.0300 -15.3300
3 C8y C 23.0300 -16.8000
4 C8y C 24.0100 -14.6300
5 N5x N 21.7000 -14.9800
6 N4y N 21.7700 -17.2900
7 N5x N 24.2200 -17.4300
8 O5x O 24.0100 -13.2300
9 N4x N 25.3400 -15.1900
10 C8x C 20.8600 -16.1700
11 C1y C 20.1600 -18.4100
12 C8y C 25.3400 -16.7300
13 C2y C 19.0400 -17.5700
14 C1x C 19.6700 -19.6000
15 N1a N 26.6000 -17.2900
16 C1y C 17.9200 -18.2700
17 C1y C 18.3400 -19.6000
18 C1b C 16.6600 -17.8500
19 O1a O 15.6100 -18.6900
20 C2a C 19.0400 -16.1700
21 O1a O 17.5000 -20.7200
BOND 22
1 2 3 2
2 2 4 1
3 2 5 1
4 3 6 1
5 3 7 1
6 4 8 2
7 4 9 1
8 5 10 2
9 11 6 1 #Up
10 7 12 2
11 11 13 1
12 11 14 1
13 12 15 1
14 13 16 1
15 14 17 1
16 16 18 1 #Up
17 18 19 1
18 6 10 1
19 9 12 1
20 16 17 1
21 13 20 2
22 17 21 1 #Down
|
|---|
